Professor and Chairman, Clinical Cancer Prevention, UT MD Anderson Cancer Center, Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, UT MD Anderson Cancer Center
I am a molecular biologist and breast medical oncologist with a primary interest in cancer prevention. My laboratory and clinical interests are to identify molecular pathways critical for cancer development and to develop clinical trials testing new strategies for cancer prevention. We are currently focused on developing molecularly targeted therapy for the prevention of estrogen receptor-negative breast cancer. We have previously shown that specific RXR-selective retinoids ("rexinoids") prevent ER-negative breast cancer in transgenic mice. These studies led us to develop and conduct a Phase II clinical trial testing the rexinoid bexarotene in women at high risk of breast cancer. We have also demonstrated that receptor tyrosine kinase inhibitors prevent ER-negative breast cancer development in mice. These results led us to develop and conduct a window-of-opportunity trial testing the signaling inhibitor lapatinib for treatment of women with DCIS breast cancer. I have also conducted other cancer prevention trials including phase II trials and the Phase III STAR Breast Cancer Prevention trial. I am the Principal Investigator of the N01 Contract that support multi-center Phase I and II early phase chemoprevention trials.
Publications/Creative Works
Click here to search for this faculty member's publications on PubMed.
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.